Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shelley Callender

Sports Medicine Macon, GA Medical Doctor

NPI 1184773939 CMS profile 937952

744 First St, Macon, GA 31201

Open in the dashboard

General payments

$404

16 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shelley Callender of Macon, GA is reported in the CMS Open Payments database as having received $404 across 16 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40 1
2022 General $169 3
2021 General $46 3
2020 General $64 4
2019 General $85 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shelley Callender
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Shelley Callender were reported at $40. Among 72 Sports Medicine profiles paid that year, the median was $60 and the middle half received between $25 and $144.

Show as a table
Year Shelley Callender Sports Medicine median Middle half National median
2019 $85 $60 $32–$131 $163
2020 $64 $37 $21–$143 $114
2021 $46 $75 $28–$196 $132
2022 $169 $66 $24–$131 $149
2023 $0 $95 $35–$136 $160
2024 $0 $93 $29–$172 $164
2025 $40 $60 $25–$144 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alexion Pharmaceuticals, Inc. $134 1 payment
  2. Merck Sharp & Dohme Corporation $86 6 payments
  3. Team 1, LLC $40 1 payment
  4. GlaxoSmithKline, LLC. $39 2 payments
  5. Pfizer Inc. $27 2 payments
  6. DePuy Synthes Sales Inc. $23 1 payment
  7. Ironshore Pharmaceuticals Inc. $21 1 payment
  8. Bayer HealthCare Pharmaceuticals Inc. $19 1 payment
  9. Mylan Pharmaceuticals Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $404 16 payments
Products named General payments · program years 2019–2025
  1. GARDASIL 9 $57 4 payments
  2. VAQTA Vaccine $43 3 payments
  3. BEXSERO $39 2 payments
  4. GARDASIL9 $28 2 payments
  5. VAQTA Vaccine $28 2 payments
  6. ROTATEQ $27 2 payments
  7. TRUMENBA $27 2 payments
  8. MONOVISC $23 1 payment
  9. Jornay PM 20mg capsules (Bottle of 100) $21 1 payment
  10. Kyleena $19 1 payment
  11. Other $122 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

473

Median for Internal Medicine: 777

Drug cost

$6,711

Median for Internal Medicine: $73,373

Branded share of claims

20.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine-Fluticasone Azelastine/Fluticasone Brand 17 $2,080
Azelastine Hcl Generic 80 $1,638
Fluticasone Propionate Generic 76 $719
Diclofenac Sodium Generic 15 $473
Methylprednisolone Generic 76 $465
Albuterol Sulfate Hfa Albuterol Sulfate Brand 12 $226
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 28 $218
Desloratadine Generic 12 $180
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 38 $161
Clindamycin Hcl Generic 12 $156

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$21,464

Of which drugs: $527

Medicare patients

222

Average age 74

Services billed

719

138 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 26%
Ischemic heart disease 26%
Depression 22%
Atrial fibrillation 20%
Chronic kidney disease 20%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 26 230 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

16 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record